ASCO Annual Meeting

Patritumab Deruxtecan Does Not Improve Survival Outcomes vs Chemo in EGFR+ NSCLC

June 3rd 2025, 4:00pm

Article

Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ advanced/metastatic NSCLC.

Kisqali Benefit Lasts Across Age in Breast Cancer Subset

June 3rd 2025, 3:00pm

Article

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.

COCOON Regimen Eases Dermatologic Side Effects After Treatment in EGFR+ NSCLC

June 3rd 2025, 2:00pm

Article

The COCOON dermatologic management regimen reduced the quality-of-life impact of Rybrevant/Lazcluze vs SOC treatment in patients with EGFR-mutated NSCLC.

Akeega Combo Delays Progression in HRR+ Castration-Sensitive Prostate Cancer

June 3rd 2025, 12:00pm

Article

Akeega delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations.

Understanding the Side Effects of RLY-2608 in HR+, HER2– Breast Cancer

June 2nd 2025, 9:00pm

Video

Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.

Imlunestrant Alone or With Verzenios Improved PROs in Advanced Breast Cancer

June 2nd 2025, 7:00pm

Article

Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy.

Fotivda Monotherapy Demonstrated Efficacy in Previously Treated Metastatic RCC

June 2nd 2025, 6:00pm

Video

Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma.

Initial Enhertu Combo Improves Survival in HER2+ Advanced Breast Cancer

June 2nd 2025, 4:00pm

Article

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, as per data from DESTINY-Breast09.

Exercise Improves Survival End Points After High-Risk CRC Treatment

June 2nd 2025, 3:00pm

Article

Participation in a structured exercise program following surgery and adjuvant chemo improved key survival end points in stage 3 and high-risk stage 2 CRC.

Breaking Down the CheckMate 901 Trial Data for Metastatic Bladder Cancer

June 2nd 2025, 2:00pm

Article

Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma.